4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
Release Date:
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial